Literature DB >> 2864273

[3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease.

C Pimoule, H Schoemaker, G P Reynolds, S Z Langer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2864273     DOI： 10.1016/0014-2999(85)90634-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  12 in total

1.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

2.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.

Authors:  M Rodriguez; G Lera; J Vaamonde; M R Luquin; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

3.  3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.

Authors:  J Kornhuber; P Riederer; G P Reynolds; H Beckmann; K Jellinger; E Gabriel
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

4.  6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.

Authors:  G R Breese; G E Duncan; T C Napier; S C Bondy; L C Iorio; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

5.  Characterization of binding of 3H-SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions.

Authors:  J Hyttel; J Arnt
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

6.  6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons.

Authors:  D G Cole; L A Kobierski; C Konradi; S E Hyman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

7.  PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.

Authors:  L Farde; C Halldin; S Stone-Elander; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.

Authors:  A Braun; G Fabbrini; M M Mouradian; C Serrati; P Barone; T N Chase
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.

Authors:  H Shinotoh; O Inoue; K Hirayama; A Aotsuka; M Asahina; T Suhara; T Yamazaki; Y Tateno
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.